about
SCYX-7158, an orally-active benzoxaborole for the treatment of stage 2 human African trypanosomiasisManagement of trypanosomiasis and leishmaniasisImmune Evasion Strategies of Trypanosoma brucei within the Mammalian Host: Progression to PathogenicityThe ever unfolding story of cAMP signaling in trypanosomatids: vive la difference!Trypanocidal activity of marine natural productsDiscovery of a Novel Class of Orally Active Trypanocidal N -Myristoyltransferase InhibitorsCrystal structures of SCP2-thiolases of Trypanosomatidae, human pathogens causing widespread tropical diseases: the importance for catalysis of the cysteine of the unique HDCF loopIn-silico investigation of antitrypanosomal phytochemicals from Nigerian medicinal plantsA static-cidal assay for Trypanosoma brucei to aid hit prioritisation for progression into drug discovery programmes.Cathepsin-L can resist lysis by human serum in Trypanosoma brucei bruceiCrovirin, a snake venom cysteine-rich secretory protein (CRISP) with promising activity against Trypanosomes and LeishmaniaPyrimidine Salvage Enzymes Are Essential for De Novo Biosynthesis of Deoxypyrimidine Nucleotides in Trypanosoma bruceiNew chemical scaffolds for human african trypanosomiasis lead discovery from a screen of tyrosine kinase inhibitor drugsIdentification of ML251, a Potent Inhibitor of T. brucei and T. cruzi Phosphofructokinase.Genetic validation of Trypanosoma brucei glutathione synthetase as an essential enzyme.Megazol and its bioisostere 4H-1,2,4-triazole: comparing the trypanocidal, cytotoxic and genotoxic activities and their in vitro and in silico interactions with the Trypanosoma brucei nitroreductase enzyme.Pharmacological validation of Trypanosoma brucei phosphodiesterases as novel drug targets.Lead optimization of a pyrazole sulfonamide series of Trypanosoma brucei N-myristoyltransferase inhibitors: identification and evaluation of CNS penetrant compounds as potential treatments for stage 2 human African trypanosomiasisPhosphodiesterase inhibitors as a new generation of antiprotozoan drugs: exploiting the benefit of enzymes that are highly conserved between host and parasite.Antiparasitic chemotherapy: from genomes to mechanisms.Development of Small-Molecule Trypanosoma brucei N-Myristoyltransferase Inhibitors: Discovery and Optimisation of a Novel Binding Mode.Deoxyhypusine Modification of Eukaryotic Translation Initiation Factor 5A (eIF5A) Is Essential for Trypanosoma brucei Growth and for Expression of Polyprolyl-containing ProteinsIn Vitro and in Vivo Activity of Multitarget Inhibitors against Trypanosoma bruceiGMP synthase is essential for viability and infectivity of Trypanosoma brucei despite a redundant purine salvage pathway.Trypanosoma brucei S-adenosylmethionine decarboxylase N terminus is essential for allosteric activation by the regulatory subunit prozymeSaponins-rich fraction of Calotropis procera leaves elicit no antitrypanosomal activity in a rat modelA review of recent patents on the protozoan parasite HSP90 as a drug targetProduct feedback regulation implicated in translational control of the Trypanosoma brucei S-adenosylmethionine decarboxylase regulatory subunit prozymeParasite prolyl oligopeptidases and the challenge of designing chemotherapeuticals for Chagas disease, leishmaniasis and African trypanosomiasisTarget-based drug discovery for human African trypanosomiasis: selection of molecular target and chemical matter.Relief of autoinhibition by conformational switch explains enzyme activation by a catalytically dead paralogDereplication strategies for targeted isolation of new antitrypanosomal actinosporins A and B from a marine sponge associated-Actinokineospora sp. EG49.Genetic validation of aminoacyl-tRNA synthetases as drug targets in Trypanosoma brucei.Parasitoses of the human central nervous system.Iron Homeostasis and Trypanosoma brucei Associated Immunopathogenicity Development: A Battle/Quest for Iron.Population pharmacokinetic modeling and deconvolution of enantioselective absorption of eflornithine in the rat.Inhibitors of Trypanosoma brucei trypanothione reductase: comparative molecular field analysis modeling and structural basis for selective inhibition.Nanobodies As Tools to Understand, Diagnose, and Treat African Trypanosomiasis.Identification of Trypanosoma brucei AdoMetDC Inhibitors Using a High-Throughput Mass Spectrometry-Based Assay.Identification and structure solution of fragment hits against kinetoplastid N-myristoyltransferase.
P2860
Q21144510-C5A2F233-1F62-4476-80EB-4E2A88A0796EQ24596889-F2994DAC-BE4B-4EE8-80E2-17DF968C02B8Q26742172-F88F5823-4F90-4A4C-8004-C5E5B34E4F93Q26781588-307BE397-4249-47B8-B66D-81E1F96F9334Q27008593-A69DCC8C-E2A8-4940-B2BE-B47B4EF1CAD3Q27676019-9DADF6A3-7E9B-493E-81FE-59FE40C41AD9Q27685322-81D28CC0-D575-4900-88BF-0996A04E5198Q28481512-DDC7C003-D3F4-4584-A919-FD6C1B89EE9AQ28485370-855BF865-1D51-489C-8282-D117A3FA51B3Q28538908-691068A1-19D2-4C20-A9FC-E714290AB218Q28543840-5B69D924-E12F-47FE-A284-51B0D9E143D0Q28553225-BF6207C8-BF5D-4BDD-8E25-BF3CDB162C95Q33622982-05DB214F-953B-47A5-A34D-565EB010C47FQ33636487-66AD04D4-9BDA-45F7-9229-6572F5520EFDQ33766769-BEA225BA-ED0D-474D-B93D-4EF4FC9FDC20Q34040586-CEDEF2A0-0D1A-4660-8F10-6E5E819C7B02Q34145529-99D0967D-2C8A-4610-A92D-8F62C6898459Q34725554-0CC21A07-8FE0-47CA-9988-D47C0F83A707Q35189546-40C742EE-2114-40CA-A767-1EC76F459A93Q35238319-CB13150D-7716-4AD4-9121-E7BF561D92E1Q35784017-454DC6E6-8AF6-4E85-8E45-9DCE02A19645Q35925923-E1DF4F87-AFBC-4D2A-B06D-A192E300F85BQ35963318-9CACA404-141B-4E54-97AA-67F9E64307D1Q35998332-0E1758F9-A864-4225-8CDC-29A6F8B9465AQ36620918-77C49A72-1F23-46FF-AE79-41E8C98B1351Q36963528-ACBB2D8F-5859-48D6-8B19-9FA297BCEB76Q36998394-E48C5A0C-4937-4D9D-9208-39349A211314Q37167161-3AC362D3-276D-4A88-913E-C28DF3ECA91EQ37186711-338D4286-A86B-46E5-9AA5-90510FE05E3CQ37449692-F4AD421A-4354-48B3-8B0A-3407FA8FCF25Q37546710-6161CACE-3770-48EF-962F-E7544FA74245Q37666966-78EEC425-2A74-4B01-A14F-8A9D88DFF467Q37723989-C78A76E8-A98B-4107-8CFF-237F09D5CA82Q38050556-534A5985-C85C-4A9D-8A32-BE79A0BB5E85Q38532068-67E2AC3B-174C-4B86-9330-08494B623517Q39212655-B44B969F-BF00-47C6-975A-0A7DD56F9791Q39329009-D0D3F578-EAA8-486E-A130-DEE9BDE6DA18Q39437960-7F06D38E-6367-42A0-BA58-82EF64C3F9D4Q40275251-3889E304-66D9-4CAD-8017-821751C73B19Q40529072-FDA061C1-F062-46E3-93AD-D06C280F9654
P2860
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on January 2011
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
State of the art in African trypanosome drug discovery.
@en
State of the art in African trypanosome drug discovery.
@nl
type
label
State of the art in African trypanosome drug discovery.
@en
State of the art in African trypanosome drug discovery.
@nl
prefLabel
State of the art in African trypanosome drug discovery.
@en
State of the art in African trypanosome drug discovery.
@nl
P2093
P2860
P1476
State of the art in African trypanosome drug discovery.
@en
P2093
Bakela Nare
Margaret A Phillips
Robert T Jacobs
P2860
P304
P356
10.2174/156802611795429167
P577
2011-01-01T00:00:00Z